Purchase Order 75N91021P00602
Award Date
9/1/21
Potential Completion Date
8/31/26
Potential Value
$590K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc. for $83,322.00. The contract provides for preventive maintenance, emergency service, support, and coverage for a government-owned Illumina NovaSeq 6000 sequencing system to support NCI's Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) clinical...
This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI) to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 DNA sequencer. The $735,959 contract has a base period of performance from March 2024 to March 2025 with four one-year option periods, and will provide preventative maintenance, remote technical support, emergency on-site repairs, and software updates to ensure uninterrupted research use of the specialized...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH), National Cancer Institute (NCI) to Illumina, Inc. for preventive maintenance and repair services on an Illumina NextSeq 2000 sequencing instrument. The contract has a ceiling value of $234,449.00 and runs for an initial 12-month period with four 12-month option periods through August 2026. There is no set-aside designation. Illumina is the original equipment manufacturer (OEM) and the only...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Illumina, Inc. for preventative maintenance service on a government-owned Illumina NextSeq 550 DNA sequencing instrument. The contract has a potential value of $189,482.72 and a completion date of March 28, 2024. It does not have any set-aside designation. As a manufacturer of genomic sequencing instruments and reagents, Illumina has...
This firm fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $235,228 contract provides for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 2000 sequencing system used in support of the NCI's research...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract provides for preventive and emergency maintenance of government-owned Illumina instrumentation, including MiSeq, cBOT, Freedom EVO, and NextSeq 500 systems, utilized for genome analysis in support of NCI's cancer research....
This is a firm fixed price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to Illumina, Inc., a manufacturer of sequencing and genomic analysis solutions. The $91,872.00 contract is for maintenance and repair services for Illumina laboratory equipment used by the agency, with a completion date of June 10, 2027. Illumina has provided sequencing systems and associated products and services to support genomic...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract valued at $300,280.00 to Illumina, Inc. for maintenance services on Illumina NextSeq 500 genomic sequencing equipment. The contract has a completion date of May 18, 2023 and was awarded on May 19, 2018. Illumina, a for-profit manufacturer of genomic analysis instruments and reagents, has been awarded numerous prime and subcontract federal awards...
The National Cancer Institute (NCI) within the National Institutes of Health (NIH) awarded a $205,376.00 firm fixed price purchase order to Illumina, Inc. for maintenance services for a government-owned Illumina NextSeq 2000 sequencing system. The base period runs from February 1, 2024 through January 31, 2028, with the potential for three one-year extensions. The contract provides for annual preventative maintenance, remote technical support, and on-site emergency repairs within two business...